Category

Daily Briefs

Daily Brief TMT/Internet: Alphabet, Argo Graphics, Plover Bay Technologies, SUMCO Corp, Ono Sokki, Perfect , Caci International, ASE Technology Holding and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • Alphabet 2Q’24 Update
  • Argo Graphics (7595) – Thursday, Apr 25, 2024
  • Alphabet Surges Past Q2 Expectations, Boosted by Digital Ads and Cloud Growth
  • Plover Bay (1523 HK): Solid H1 FY24, Inflection Point In Earnings
  • Tech Supply Chain Tracker (26-Jul-2024): NCKU in Taiwan achieves semiconductor precision breakthrough.
  • Ono Sokki (6858 JP): 1H FY12/24 flash update
  • Perfect Corp – July 25, 2024
  • PERF: New AI Assistant Could Revolutionize In-Store and Online Sales Just as AI did to Customer Service
  • Caci Intl Inc -Cl A (CACI) – Wednesday, Apr 24, 2024
  • ASEH (3017.TT; ASX.US): ​Selective Products Have Hit Bottom While General Products Lag Behind.


Alphabet 2Q’24 Update

By MBI Deep Dives

  • Yesterday’s Google’s earnings may have been bit of “meh” at first glance, but there were nuggets in the call that may have important implications for the broader market.
  • Network segment continues to struggle, but the rest of the businesses continue to grow at healthy double digit rate.
  • Search revenue growth surpassed YouTube ads revenue growth last quarter. For the first time, Cloud posted >$10 Bn quarter while maintaining high 20s growth YoY.

Argo Graphics (7595) – Thursday, Apr 25, 2024

By Value Investors Club

  • Arco Graphics is a strategic reseller of industrial CAD and semiconductor fab ERP software in Japan, representing Dassault Systems and IBM
  • Despite consistent EBIT growth over the past 7 years, the company’s valuation remains attractive for investors
  • Expected to announce better-than-guided results for Fiscal 2023 in May, along with an improved shareholder returns strategy

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Alphabet Surges Past Q2 Expectations, Boosted by Digital Ads and Cloud Growth

By Uttkarsh Kohli

  • Alphabet’s revenue jumped 14% YoY to $84.74B, exceeding the $84.19B forecast, fueled by strong digital ad sales and cloud services demand.
  • Net income rose 28.6% to $23.6B, surpassing the $22.9B estimate, reflecting effective cost management and revenue growth despite margin concerns.
  • YouTube’s ad revenue fell short of expectations, growing slower than Q1 due to increased competition and tougher year-on-year comparisons, impacting overall share performance.

Plover Bay (1523 HK): Solid H1 FY24, Inflection Point In Earnings

By Sameer Taneja

  • Plover Bay Technologies (1523 HK) reported 28.4%/55 % YoY revenue/net profit growth, led by growth from new customers in the US, Australia, and Europe. 
  • The company reiterated its long-term guidance of reaching 300 mn USD revenue (FY23: 94 mn USD) in less than ten years. There was no clear guidance for FY24. 
  • The stock trades at 14.8x PE FY24e, with a 5.4% dividend yield (assuming an 80% payout), and is at the cusp of an inflection in its growth. 

Tech Supply Chain Tracker (26-Jul-2024): NCKU in Taiwan achieves semiconductor precision breakthrough.

By Tech Supply Chain Tracker

  • NCKU in Taiwan achieves breakthrough in angstrom-scale semiconductor precision, potentially revolutionizing the industry.
  • Uncertainty surrounds impact of Trump win on green energy, with transition likely to be slower but not impossible.
  • Apple introduces new open-source AI models, Kyushu attracts record investments from TSMC, while SK Hynix experiences sales/profit growth. Vietnam partners with Qorvo, Cadence to train 50,000 engineers by 2030.

Ono Sokki (6858 JP): 1H FY12/24 flash update

By Shared Research

  • Orders for 1H FY12/24 totaled JPY7.1bn (+27.0% YoY), with Measuring Equipment at JPY2.3bn (+14.9% YoY) and Custom Order Test Equipment and Services at JPY4.8bn (+33.7% YoY).
  • Operating loss expanded to JPY478mn, recurring loss to JPY457mn, and net profit attributable to owners of the parent was JPY884mn due to a JPY1.9bn gain from the sale of fixed assets.
  • Full-year FY12/24 forecast: Sales JPY12.5bn (+8.3% YoY), Operating profit JPY300mn (+115.8% YoY), Recurring profit JPY330mn (+61.8% YoY), Net income JPY1.6bn (+253.9% YoY).

Perfect Corp – July 25, 2024

By Zacks Small Cap Research

  • Perfect Corp. provides an AI and machine learning based B2B SaaS platform for virtual try on and marketing of beauty and fashion products as well as six mobile apps sold B2C for makeup suggestions, try-on, tutorials, photo and video editing and most recently, Gen AI creation and editing.
  • It is expanding its offering to new verticals and has strong IP as well as the largest database for AI training in the industry.
  • It has a dominant market share and serves almost all the major beauty brands worldwide.

PERF: New AI Assistant Could Revolutionize In-Store and Online Sales Just as AI did to Customer Service

By Zacks Small Cap Research

  • Perfect Corp. provides an AI and machine learning based B2B SaaS platform for virtual try on and marketing of beauty and fashion products as well as six mobile apps sold B2C for makeup suggestions, try-on, tutorials, photo and video editing and most recently, Gen AI creation and editing.
  • It is expanding its offering to new verticals and has strong IP as well as the largest database for AI training in the industry.
  • It has a dominant market share and serves almost all the major beauty brands worldwide.

Caci Intl Inc -Cl A (CACI) – Wednesday, Apr 24, 2024

By Value Investors Club

  • CACI’s stock price has decreased by approximately 4%
  • The company has a strong presence in government services and defense sectors
  • CACI is considered an undervalued investment opportunity with potential for significant growth in the future

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


ASEH (3017.TT; ASX.US): ​Selective Products Have Hit Bottom While General Products Lag Behind.

By Patrick Liao

  • General products did not show an immediate recovery, but selective products have reached the bottom.    
  • The 3Q24 sales will grow in the mid to high teens QoQ in EMS, and IC-ATM sales will grow in the mid to high single digits QoQ.  
  • AI remains strong across all sectors. Despite AI SP driving the replacement cycle, other general demands still show muted recovery in 3Q24.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Saizeriya, Zomato, Canon Marketing Japan, TSE Tokyo Price Index TOPIX, Garrett Motion, Pvh Corp, Shoppers Stop and more

By | Consumer, Daily Briefs

In today’s briefing:

  • Saizeriya (7581 JP):  Improvement In Profitability In Japan Materialized in 3Q24
  • Quiddity Leaderboard BSE/​​​​SENSEX Dec 24: Could Zomato’s Share Price Rally Become a Problem?
  • Canon Marketing Japan (8060 JP): 1H FY12/24 flash update
  • Although the Cost of Capital for CBs Should Be Considered Much Higher than for SBs
  • GTX: Value from Impatience
  • Pvh Corp – VNCE: Snapping the Store: Pre-Fall Continues to Impress; Reiterate Buy, $3 PT
  • Narrative and Numbers | Shoppers Stop (SHOP IN) | FY24


Saizeriya (7581 JP):  Improvement In Profitability In Japan Materialized in 3Q24

By Steve Zhou, CFA

  • Since the release of 3Q24 (YE August) results on July 10, the share price of Saizeriya (7581 JP) is up nearly 10%, greatly outperforming Nikkei during the same time frame. 
  • The 3Q24 results showed that Japan’s operating profit finally improved, while China remained solid. 
  • The company is currently trading at 24x 2025E PE with strong earnings growth.

Quiddity Leaderboard BSE/​​​​SENSEX Dec 24: Could Zomato’s Share Price Rally Become a Problem?

By Janaghan Jeyakumar, CFA

  • In this insight, we take a look at the Potential ADDs/DELs for the BSE SENSEX, 100, and 200 indices in the December 2024 index rebal event.
  • At present, 3 changes for the BSE 100 index and 7 changes for the BSE 200 index.
  • The BSE 100 handling rules for names without futures and options (F&O) sometimes punish companies that have enjoyed good share price rallies and Zomato could get into such a trap.

Canon Marketing Japan (8060 JP): 1H FY12/24 flash update

By Shared Research

  • Sales rose 5.3% YoY to JPY318.9bn, driven by strong SI and IT infrastructure services; operating profit fell 3.9% YoY.
  • FY12/24 sales forecast revised to JPY650.0bn (+6.6% YoY) due to Primagest acquisition and strong IT solutions performance.
  • Segment forecasts: Consumer sales flat, Enterprise sales JPY236.2bn (+7% YoY), Professional sales JPY44.0bn (+9% YoY).

Although the Cost of Capital for CBs Should Be Considered Much Higher than for SBs

By Aki Matsumoto

  • We need to watch carefully to see whether cash flow will subsequently increase in the projects that the CB issuers have invested their proceeds in.
  • Share prices of companies that announce equity financings, including CBs, usually decline. Besides the dilution, another aspect is the effect of the company’s announcement of the sale of its shares.
  • In the case of CBs, the company should keep in mind that it sold the conversion rights of its shares for less than their actual call option value.

GTX: Value from Impatience

By Hamed Khorsand

  • GTX reported Q2 results missing our estimates as demand for turbochargers softened in quarter. The magnitude of the sales miss was amplified by deflationary cost pass throughs.  
  • GTX was successful in maneuvering its cost structure at the beginning 2024 resulting in gross margin exceeding our estimate and adjusted EBITDA declining by a significantly smaller amount than sales. 
  • We were already towards the low end of GTX’s previous guidance range anticipating uncertainty. Our adjustments to 2024 and 2025 adjusted EBITDA estimates are minimal.

Pvh Corp – VNCE: Snapping the Store: Pre-Fall Continues to Impress; Reiterate Buy, $3 PT

By Small Cap Consumer Research

  • We are reiterating our Buy rating, projections and $3 price target for Vince after visiting stores in Long Island, Connecticut and New Jersey.
  • We believe the company continues to roll out winning collections, with a focus on compelling hues (dark scarlet and blue waltz), new items (cargo pants, shrunken camisoles, silk hooded shirts and cardigan sweaters) and a deeper focus on key categories such as dresses.
  • Further, we are also seeing continued newness and expansion in men’s, driven by jackets, button front shirts (in patterns and textures) and the beginnings of a colder weather focus on long sleeve items, including the return of the waffle shirt jacket.

Narrative and Numbers | Shoppers Stop (SHOP IN) | FY24

By Pranav Bhavsar

  • Shoppers Stop (SHOP IN) is a leading retailer in India specializing in fashion and beauty brands with 12 department stores, 7 premium home stores, and 87 specialty beauty outlets,
  • SHOP has also launched its value retail format INTUNE in June 2023 generating excitement and interest around the same. 
  • It seems SHOP is trying to play all cards of the retail game, i.e., premium, beauty, and value fast fashion, but so far has shown no signs of success.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Genscript Biotech, Arvida, Jeisys Medical, Embecta , Fusion Pharmaceuticals , Ainos and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • StubWorld: Legend (LEGN US) Offer Or Not, Genscript (1548 HK) Is Attractive
  • Arvida (ARV NZ): Stonepeak’s Offer
  • Arvida Group (ARV NZ): Stonepeak’s Binding Proposal at NZ$1.70
  • Jeisys Medical (287410 KS): Archimed Reloads Delisting Offer
  • Embecta Corp Exploring A Potential Sale! Is This The Much Needed Move For A Potential Turnaround? – Financial Forecasts
  • Fusion Pharmaceuti Inc (FUSN) – Wednesday, Apr 24, 2024
  • Ainos, Inc. Water Tower Hour Recap: AI Nose for POCT Diagnostics and Much More


StubWorld: Legend (LEGN US) Offer Or Not, Genscript (1548 HK) Is Attractive

By David Blennerhassett

  • Biotech play Genscript Biotech (1548 HK) and ~48%-held Legend Biotech (LEGN US) popped recently on a reported tilt for Legend.  Neither Genscript nor Legend made exchange announcements supporting the claim. 
  • Preceding my comments on Genscript/Legend are the current setup/unwind tables for Asia-Pacific Holdcos.
  • These relationships trade with a minimum liquidity of US$1mn, and a % market capitalisation >20%.

Arvida (ARV NZ): Stonepeak’s Offer

By David Blennerhassett

  • Arvida (ARV NZ), a leading retirement living and aged care service provider in New Zealand, announced a Scheme from PE-outfit Stonepeak at NZ$1.70/share, in cash, a 65% premium to undisturbed. 
  • The Offer has unanimous board support. ~18% of shares out are supportive. Standard Scheme voting applies. Consent from NZ’s Overseas Investment Office also required. 
  • A Scheme Meeting is expected to be held in 4Q24 with implementation in the same quarter. Optics are a tad opportunistic; but this looks priced to complete. 

Arvida Group (ARV NZ): Stonepeak’s Binding Proposal at NZ$1.70

By Arun George

  • On 22 July, Arvida (ARV NZ) entered a scheme implementation agreement with Stonepeak at NZ$1.70, a 65.0% premium to the undisturbed price.
  • The transaction will require OIO approval, statutory supervisors’ consent and shareholder approval. The Metlifecare Ltd (MET NZ) precedent suggests that the OIO and statutory supervisor should be forthcoming.
  • The offer is attractive, and shareholders representing 18% of outstanding shares are supportive. At the last close and for a November payment, the gross/annualised spread was 4.9%/14.2%.  

Jeisys Medical (287410 KS): Archimed Reloads Delisting Offer

By David Blennerhassett

  • Last month, aesthetic laser maker Jeisys Medical (287410 KS) announced French PE outfit Archimed SAS was seeking to delist the company.
  • Via a Tender Offer, Archimed sought to acquire 72% of Jeisys at ₩13,000. Archimed also inked agreements with founders/directors for 26.44%, taking its possible % holding to 98.44%.
  • The Tender Offer closed on the 22nd July with Archimed holding 81.39% (including the aforementioned agreements). Archimed has now reloaded, on the same terms. There is no minimum acceptance condition. 

Embecta Corp Exploring A Potential Sale! Is This The Much Needed Move For A Potential Turnaround? – Financial Forecasts

By Baptista Research

  • Embecta is in an intricate phase as strategists contemplate its potential as an acquisition target.
  • Analyzing Embecta’s scenario involves balancing an array of factors highlighted during its thorough earnings discussion.
  • On the positive side, Embecta has displayed a robust earnings performance in the fiscal second quarter of 2024, with a total revenue growth of 3.6% on an as-reported basis and 4.5% on a constant currency basis.

Fusion Pharmaceuti Inc (FUSN) – Wednesday, Apr 24, 2024

By Value Investors Club

  • Fusion Pharmaceuticals is being acquired by AstraZeneca for $21 in cash and a $3 CVR
  • Fusion presented promising results from its phase II trial, showing consistent safety signals
  • The acquisition demonstrates continued interest and investment in the biotech industry

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Ainos, Inc. Water Tower Hour Recap: AI Nose for POCT Diagnostics and Much More

By Water Tower Research

  • Ainos business and priorities. The medtech company has three key technology platforms: (1) AI Nose point of care testing (POCT); (2) Low dose interferon-α Veldona; and (3) Synthetic RNA in early discovery stage.
  • Priorities for AI Nose are Ainos Flora (POCT diagnostic for women vaginal health and STIs) and a health monitor system for elderly care in co-development.
  • Veldona will focus on oral warts in HIV+ patients and Sjogren’s syndrome, in addition to cat FCGS (gum disease) for animal health.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: Korea Stock Exchange Kospi Index, Yes Bank, Ashford Inc, P10 Inc, Ethereum and more

By | Daily Briefs, Financials

In today’s briefing:

  • Overall Assessment of the Value-Up Policy-Related Aspects of the Tax Reform Plan Released Today
  • Yes Bank’s Retail Therapy Proves Expensive
  • Ashford Inc (AINC) – Wednesday, Apr 24, 2024
  • P10 Inc (PX) – Wednesday, Apr 24, 2024
  • Crypto Moves #36 – Give the Ethereum ETFs a Week, Then It Is Up Only


Overall Assessment of the Value-Up Policy-Related Aspects of the Tax Reform Plan Released Today

By Sanghyun Park

  • The highest dividend tax rate drops from 49.5% to 25%, leading the local capital market to view the reform as more shareholder-focused than company-focused.
  • The top inheritance tax rate drops from the 60% range to 40%, a meaningful reduction for conglomerates like Hyundai and Hanwha, though below initial expectations.
  • Tax incentives in the reform are less aggressive than expected, with modest corporate and inheritance tax cuts. However, this compromise increases the likelihood of its passage, boosting short-term market expectations.

Yes Bank’s Retail Therapy Proves Expensive

By Hemindra Hazari

  • Reconstructed board of Yes Bank implemented an ill-conceived, poorly executed retail strategy to revive the bank
  • Structural problem of low net interest margin and high overheads not resolved
  • Retail assets strategy characterised by low yield, high operating cost and rising credit cost which the bank has finally acknowledged

Ashford Inc (AINC) – Wednesday, Apr 24, 2024

By Value Investors Club

  • Ashford Inc. has approved a going dark transaction offering $5.00 cash per share to common stockholders with fewer than 10,000 shares
  • Potential profits of $2,300 using 9,999 shares represent a 4.8% return, annualizing to 19.2% due to a projected July closing
  • AINC is a hotel management company led by Monty Bennett, and the transaction is subject to a stockholder vote and IRA Waiver Proposal, with directors and executive officers expressing their support.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


P10 Inc (PX) – Wednesday, Apr 24, 2024

By Value Investors Club

  • P10 is an alternative asset manager providing access to private markets, charging fees on committed capital over a 10-to-15-year period.
  • Recent decrease in cash margins due to factors like strategy mix shift and CEO transition has led to P10 trading at a highly discounted multiple of AUM and revenue.
  • Valuation uncertainty and disappointing growth forecasts for 2024 may be offset by potential for growth and re-rating of equity with new CEO focused on improving FPAUM and margins.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Crypto Moves #36 – Give the Ethereum ETFs a Week, Then It Is Up Only

By Mads Eberhardt

  • The U.S.-based Ethereum spot ETFs were launched on Tuesday, concluding their second trading session yesterday.
  • Since the launch, Ethereum has declined slightly both in dollar terms and relative to Bitcoin.
  • Despite this situation, there is nothing to fear – in fact, quite the opposite, as we will demonstrate in today’s Crypto Moves.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Technical Analysis: Monitoring Small- Vs. Large-Caps and Growth Vs. Value; $SPX and more

By | Daily Briefs, Technical Analysis

In today’s briefing:

  • Monitoring Small- Vs. Large-Caps and Growth Vs. Value; $SPX, $QQQ in Pullback Mode


Monitoring Small- Vs. Large-Caps and Growth Vs. Value; $SPX, $QQQ in Pullback Mode

By Joe Jasper

  • Breadth has expanded significantly in recent weeks with the Russell 2000 (IWM) breaking above major 2.5-year resistance at $210; $210 is now critical support moving forward.
  • Technology/Large-Cap growth/Nasdaq 100 (QQQ) has consolidated after getting extended, and with June 12 gap support on QQQ getting filled/breaking today, it appears this pullback is likely to continue.
  • The SPX is breaking its 20-day MA. June 12th gap at 5375-5409 is potential support, but it appears a pullback in the SPX and QQQ may be headed to 5191/$449.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Thematic (Sector/Industry): Ohayo Japan | Biggest Drop Since 2022 and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Ohayo Japan | Biggest Drop Since 2022
  • # 33 India Insight: Paytm Collaborates with Axis, Gland Pharma Approval, Tata Consumer Right Issue
  • WTR Furniture/Furnishings 2H24 Industry Outlook


Ohayo Japan | Biggest Drop Since 2022

By Mark Chadwick

  • U.S. stocks plunged on Wednesday, driven by a 3.6% drop in the Nasdaq Composite
  • Canon Marketing Japan announced a tender offer to buy back up to 90 billion yen of its own
  • Furukawa Electric will build new plants in Japan and the Philippines to produce water-cooled systems for data centers

# 33 India Insight: Paytm Collaborates with Axis, Gland Pharma Approval, Tata Consumer Right Issue

By Sudarshan Bhandari

  • Paytm and Axis Bank collaborate to enhance POS solutions, integrating advanced card payment devices.
  • Gland Pharma and Zydus Lifesciences secure key USFDA approvals for new medications.
  • Tata Consumer announces a Rs 3,000 crore rights issue to bolster financial position and growth.

WTR Furniture/Furnishings 2H24 Industry Outlook

By Water Tower Research

  • Equity analysts spend most of their time trying to get a handle on what is going to happen over the next 12-24 months for the companies that they follow.
  • Much of the focus is on ‘the numbers’. But sometimes it’s useful to pause and take some time to think about the big picture factors that could affect the industries and companies we care about.
  • In this industry report, we talk about five of the current themes and one trend we have been thinking about, with an eye on how they may affect the furniture and furnishings industries (both residential and contract/commercial) going forward

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Credit: Morning Views Asia: ENN Natural Gas and more

By | Credit, Daily Briefs

In today’s briefing:

  • Morning Views Asia: ENN Natural Gas


Morning Views Asia: ENN Natural Gas

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Korea’s New IPO Bookbuilding & Lockup Results Disclosure Rule and more

By | Daily Briefs, ECM

In today’s briefing:

  • Korea’s New IPO Bookbuilding & Lockup Results Disclosure Rule, Effective from August
  • Technically Speaking, Breakouts and Breakdowns: HONG KONG (July 24)
  • Akums Drugs and Pharmaceuticals Pre-IPO – Profitable but Needs to Scale up More
  • Timee IPO Trading – Garnered a Strong Demand, Should Pop
  • Amer Sports IPO Lock-Up Expiry – PE Investor Might Look to Trim US$750m Stake


Korea’s New IPO Bookbuilding & Lockup Results Disclosure Rule, Effective from August

By Sanghyun Park

  • FSS’s leaked IPO guidelines include new, highly attention-grabbing additions: specifically, the disclosure of extra information from the bookbuilding and lockup results not mentioned in May.
  • Institutions submitting prices outside the indicative band must be disclosed by KRX investor type. Additionally, average placed price information for lockup-pledged investors must be disclosed.
  • FSS will distribute new IPO guidelines this week and apply them from next month. Major IPOs like K Bank must disclose more detailed bookbuilding and lockup results, impacting trading dynamics.

Technically Speaking, Breakouts and Breakdowns: HONG KONG (July 24)

By David Mudd

  • BYD (1211 HK) shares had a breakout relative to the MSCI China index and showing good momentum during the low volume days of summer. 
  • POWER ASSETS HOLDINGS (6 HK) has shown a breakout relative to MSCI Hong Kong with a defensive business and 5%+ dividend yield.
  • WH GROUP (288 HK) has also shown a breakout relative to the MSCI Hong Kong after its announcement of the spinoff of Smithfield Foods in the US.

Akums Drugs and Pharmaceuticals Pre-IPO – Profitable but Needs to Scale up More

By Ethan Aw

  • Akums Drugs and Pharmaceuticals (0200361D IN) is looking to raise up to US$239m in its upcoming India IPO. 
  • Akums Drugs and Pharmaceuticals (ADP) is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
  • In this note, we talk about the company’s historical performance.

Timee IPO Trading – Garnered a Strong Demand, Should Pop

By Clarence Chu

  • Timee Inc (215A JP) raised US$300m in its Japan IPO. The IPO had been a 100% secondary selldown by existing shareholders.
  • Timee operates an on-demand staffing platform that connects part-time jobseekers with businesses in Japan.
  • We have looked at the company’s past performance in our previous notes. In this note, we talk about the trading dynamics.

Amer Sports IPO Lock-Up Expiry – PE Investor Might Look to Trim US$750m Stake

By Sumeet Singh

  • Amer Sports (AS US) raised around US$1.3bn in its US IPO in Feb 2024, after pricing its IPO below its initial range.
  • Amer Sports is a sports and outdoor brands company making clothing and other sporting equipment for use in snow sports, running, climbing, baseball, american football, tennis and other sports.
  • In this note, we talk about the upcoming lock-up expiry and deal dynamics.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Equity Bottom-Up: [Earnings Preview] Weak Refining Margins and Gas Prices Dampen Chevron’s Q2 Earnings Outlook and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • [Earnings Preview] Weak Refining Margins and Gas Prices Dampen Chevron’s Q2 Earnings Outlook
  • GES: Snapping the Store: Summer Begins to Sizzle; Reiterate Buy, $37 PT
  • [Q2 Earnings Preview] Meta’s Ad Revenues Expected to Surge, But Rising Spend Remains a Concern
  • Yeo Hiap Seng (YHS SP): Healthy Drinks, Thirsty Shareholders
  • Axon: Stunning The Competition – [Business Breakdowns, EP.175]
  • Samsung Biologics (207940 KS): Strong 2Q24 Result; Annual Revenue to Surpass KRW4 Trillion
  • ESG Brew with ComfortDelGro’s Group Chief Sustainability and Risk Officer: ‘Our transition to cleaner energy vehicles will be a game-changer’
  • JAKK: 2Q Preview: Setting up for Success; Reiterate Buy Rating, $24 PT
  • Tech Supply Chain Tracker (25-Jul-2024): BOE boosts S. Korean suppliers, Wonik gets more orders
  • Ainos, Inc. – Veldona Animal Study Enrolls First Subject, Marking a Good Start


[Earnings Preview] Weak Refining Margins and Gas Prices Dampen Chevron’s Q2 Earnings Outlook

By Suhas Reddy

  • Chevron’s Q2 revenue is set to dip 0.6% YoY, with EPS projected to drop 4.5% YoY on the back of lower refinery margins and natural gas prices.
  • Higher Brent crude prices and strong production may help Chevron partially offset Q2’s challenges.
  • Unplanned downtime at two Australian LNG plants during Q2 raises concerns about a drop in production.

GES: Snapping the Store: Summer Begins to Sizzle; Reiterate Buy, $37 PT

By Small Cap Consumer Research

  • We are reiterating our Buy rating, $37 price target and projections for Guess?
  • after visiting stores in Long Island and the Metropolitan New York City area.
  • With the return of hot and humid weather, we believe Guess?

[Q2 Earnings Preview] Meta’s Ad Revenues Expected to Surge, But Rising Spend Remains a Concern

By Uttkarsh Kohli

  • Meta is expected to report a 58% YoY increase in EPS to $4.71, with revenue climbing 20% YoY to $38.29B, driven by robust ad performance.
  • Meta plans a 20% cut in Reality Labs’ budget through 2026, aiming to save $3B while shifting focus to upcoming hardware production.
  • In Q1, increased daily active users and a 6% rise in average ad prices have boosted Meta’s ad revenue, despite heightened competition and regulatory pressures. Likely to continue.

Yeo Hiap Seng (YHS SP): Healthy Drinks, Thirsty Shareholders

By Devi Subhakesan

  • Yeo Hiap Seng(YHS SP) , known for its Yeo’s brand of Asian/health drinks, trades near its 52-week low at SGD 0.55, despite having financial assets and cash worth SGD 0.44/share.
  • With limited guidance on reinvestment/growth opportunities and management’s stance against returning cash to shareholders, the stock trades around dividend yield, now at 3.6%.
  • Over the past decade, the stock has lost 75% of its value, and management must take decisive actions to enhance long-term shareholder value.

Axon: Stunning The Competition – [Business Breakdowns, EP.175]

By Business Breakdowns

  • Axon sells a public safety technology ecosystem that includes three main product groups, TASERs, body-worn cameras and other sensors, and evidence software, amongst a host of other software services, including virtual reality training.
  • Axon’s solutions really seek to solve three of the biggest problems facing public safety, too many officers and too many suspects are dying from gunshots.
  • Axon solves for this is as the monopoly provider of TASERs globally. A TASER can be used as an alternative to firearms to temporarily incapacitate a suspect so that they may be restrained with a much, much lower chance of doing physical harm.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Samsung Biologics (207940 KS): Strong 2Q24 Result; Annual Revenue to Surpass KRW4 Trillion

By Tina Banerjee

  • In 2Q24, Samsung Biologics (207940 KS) reported 34% YoY revenue growth to KRW1,157B, driven by full utilization of Plants 1–3, ramp-up of Plant 4, milestone payment, and favorable Fx.
  • The company expects annual revenue to exceed KRW4T mark this year, thereby setting a record for the Korean pharmaceutical and biotechnology sector.
  • During 1H24, Samsung Biologics has secured order worth of KRW2.6T. Currently, the company is serving 16 out of the top 20 global pharmaceutical companies, up from 14 last year.

ESG Brew with ComfortDelGro’s Group Chief Sustainability and Risk Officer: ‘Our transition to cleaner energy vehicles will be a game-changer’

By Geoff Howie

  • ESG Brew with ComfortDelGro’s Group Chief Sustainability and Risk Officer: ‘Our transition to cleaner energy vehicles will be a game-changer’ Land transport operator ComfortDelGro is switching its fleet of over 40,000 vehicles in 12 countries to cleaner energy ones as part of its sustainability drive.
  • Jong explains: “We operate in 12 countries with a total fleet of over 40,000 vehicles spanning taxis, buses, trains and more.

JAKK: 2Q Preview: Setting up for Success; Reiterate Buy Rating, $24 PT

By Small Cap Consumer Research

  • We are reiterating our Buy rating, projections and $24 price target for JAKKS Pacific with the company announcing 2Q24 (June) results after the close on Wednesday.
  • While we do not expect, nor have we projected, a strong 2Q, we do believe management will be upbeat on a number of key fronts, including: 1) Cleaning up inventory levels in anticipation of Holiday strength and new launches; 2) gearing up for more normalized Halloween costume demand; 3) initial launches for The Simpsons lines to key domestic and international retailers; 4) progress on the international expansion front; 5) the initial shipments for the Authentic Brands partnership and 6) potential demand for Moana 2 and Sonic the Hedgehog 3 Holiday movies.
  • Further, we expect the balance sheet has remained debt free, cash rich and management will provide an update on potential return to shareholders.

Tech Supply Chain Tracker (25-Jul-2024): BOE boosts S. Korean suppliers, Wonik gets more orders

By Tech Supply Chain Tracker

  • BOE’s B16 OLED commitment boosts Korean suppliers, Wonik to see surge in orders
  • Offshore wind delays in Taiwan lead to focus on Japan and Korea for opportunities
  • Onsemi chosen to power VW EV, Elon Musk supports Trump’s EV policies, tariff war on chips impacts consumers and companies

Ainos, Inc. – Veldona Animal Study Enrolls First Subject, Marking a Good Start

By Water Tower Research

  • Enrolled first subject in feline oral disease study, paving way for animal health opportunity.
  • The randomized, double- blind Veldona animal study will enroll 30 cats with feline chronic gingivostomatitis (FCGS) at a single Taiwan clinical site.
  • Two dosage groups, a low dose (6,000 IU) and high dose (12,000 IU), will be evaluated. The first enrolled subject will be dosed later this week. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Event-Driven: Sep24 S&P500 Index Rebal – Two Changes Expected; $6bn One-Way Flow and Two Spinoffs? and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • Sep24 S&P500 Index Rebal – Two Changes Expected; $6bn One-Way Flow and Two Spinoffs?
  • Tohokushinsha (2329 JP) – 3D Investment Partners Proposes Take-Private
  • FSS Orders Doosan Group to Resubmit the Merger Plan – “Merger Plan Is Not Illegal, But Is It Fair?”
  • CPMC Holdings (906 HK): Decisions, Decisions as Changping Industrial’s Offer Set to Open
  • Clarifications Regarding the FSS’s Unexpected Revision Request for the Doosan Mergers
  • CPMC Holdings (906.HK) Privatization Update – The Story Behind the Delay of Offer Document Despatch
  • Archimed Group Plans to Conduct a Second Tender Offer for Jeisys Medical
  • Shinsung Tongsang: Tender Offer Fails and How to Take Away Customers From Uniqlo
  • KOSPI Size Indices: Outperformance Slows on Momentum Stalls
  • Hanwha Energy Acquires An Additional 5.2% of Hanwha Corp Through a Tender Offer


Sep24 S&P500 Index Rebal – Two Changes Expected; $6bn One-Way Flow and Two Spinoffs?

By Travis Lundy

  • The S&P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.
  • In this insight, we take a look at the upcoming constituent changes in the run up to the September 2024 index rebal event.
  • We expect two regular changes during September. More interestingly, a couple of SP500 members are working on spin-offs which could trigger some high-impact deletions over the next few months.

Tohokushinsha (2329 JP) – 3D Investment Partners Proposes Take-Private

By Travis Lundy

  • 3D Investment Partners, known to be activist-ish-y, purchased 18% of Tohokushinsha Film (2329 JP) in the 12 months to March 2024. They started a public activism campaign in February.
  • The company has started down a better governance track, but now 3D has made a takeover proposal to Tohokushinsha, which will consider it under Special Committee.
  • There are a couple of possible outcomes here which are interesting to consider. There are no other spoilers possible except those friendly to founders and management.

FSS Orders Doosan Group to Resubmit the Merger Plan – “Merger Plan Is Not Illegal, But Is It Fair?”

By Douglas Kim

  • On 24 July, the Financial Supervisory Service (FSS) ordered the Doosan Group to resubmit the merger plan. 
  • It is rare for FSS to reject companies’ merger reports but there has been an exception this time since this deal is egregiously negative to many minority investors.
  • Doosan Group needs to resubmit a revised merger plan within next three months. Otherwise, the securities report involving the merger plan of the Doosan Group companies will be considered withdrawn. 

CPMC Holdings (906 HK): Decisions, Decisions as Changping Industrial’s Offer Set to Open

By Arun George

  • On 15 July, the precondition for Changping Industrial’s HK$6.87 offer for CPMC Holdings (906 HK) was satisfied, but the despatch of the offer document was delayed until or before 30 July.
  • Since ORG Technology Co., Ltd. A (002701 CH) announced its HK$7.21 offer on 7 June, the shares have traded above Changping Industrial’s offer on all but bar one trading day
  • Changping Industrial has three options: launch at unchanged terms (low probability), match ORG’s offer (medium probability) or bump marginally higher than ORG’s offer (high probability).

Clarifications Regarding the FSS’s Unexpected Revision Request for the Doosan Mergers

By Sanghyun Park

  • The FSS requested Doosan Robotics to revise the prospectuses for both the Share Swap with Doosan Bobcat and Merger with Doosan Enerbility.
  • Although the FSS’s wording seems aggressive, it does not request the cancellation. Authorities are displeased but lack political momentum to derail Doosan’s restructuring.
  • The FSS asks Doosan to clarify merger synergies, warn of Robotics’ overvalued stock price and potential decline, and highlight the collaborative robot market’s growth risks.

CPMC Holdings (906.HK) Privatization Update – The Story Behind the Delay of Offer Document Despatch

By Xinyao (Criss) Wang

  • Since all the Pre-Conditions have been fulfilled, Baosteel has taken a solid step towards the successful acquisition of CPMC. Comparatively, ORG could encounter resistance and uncertainties in the upcoming process.
  • The acquisition of CPMC by ORG cannot be completed by ORG and Zhang Wei alone.Without the “nod” of COFCO/SASAC, what ORG’s going to do is equivalent to a “hostile takeover”. 
  • ORG’s acquisition of control of CPMC could go against the national strategy of “building strong alliances between SOEs”. In fact, what ORG wants is for Baosteel to raise its Offer.

Archimed Group Plans to Conduct a Second Tender Offer for Jeisys Medical

By Douglas Kim

  • In the first tender offer, 42.5 million shares of Jeisys Medical were purchased by Archimed Group. Post tender offer, Archimed now owns an 82.1% stake in Jeisys Medical. 
  • On 24 July, it was announced that Archimed will be conducting a second tender offer for Jeisys Medical. The second tender offer will be made for 17.2% of common shares.
  • It could be difficult for Archimed to gain more than 95% stake at the end of the second tender offer. Rather, a third tender offer is likely in 2025.

Shinsung Tongsang: Tender Offer Fails and How to Take Away Customers From Uniqlo

By Douglas Kim

  • Shinsung Tongsang shares rose 10% to 2,510 won today after it was announced that the tender offer failed. Basically, the tender offer failed because the tender offer price was too low. 
  • Only 26% of the 31.664 million shares responded to the tender offer. Accordingly, the shareholding ratio of Chairman Yeom and his related parties increased from 77.98% to 83.88%. 
  • Top Ten has benefited from executing its strategy well (such as employing Lee Na-Young in advertisements to grab customers from Uniqlo). Overall, we remain positive on Shinsung Tongsang.

KOSPI Size Indices: Outperformance Slows on Momentum Stalls

By Brian Freitas

  • The review period for the September rebalance of the KOSPI Size Indices commenced on 1 June and will end on 31 August.
  • We see 8 migrations from MidCap to LargeCap, 1 new addition to LargeCap, 11 stocks moving from SmallCap to MidCap and 3 new additions to MidCap.
  • There are a few stocks that are expected to have passive flows from global and local index trackers over the next few months and that will add to the impact.

Hanwha Energy Acquires An Additional 5.2% of Hanwha Corp Through a Tender Offer

By Douglas Kim

  • After the market close on 24 July, Hanwha Corporation (000880 KS) announced that Hanwha Energy secured an additional 5.2% stake in Hanwha Corp through a tender offer.
  • A total of 3.9 million shares have been applied for the tender offer as of 24 July (65% of targeted amount). 
  • We believe that the Hanwha Group is likely to grab more shares in Hanwha Corp through an additional tender offer sometime in the next 6-12 months. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars